 |
 |
 |
 |
 |
 |
 |
 |
 • Overview • Directors • Senior Management  • The Original Ikaria • INO Therapeutics • The Name 'Ikaria' |
 Ikaria Holdings is an investment company that combines two companies into one fully-integrated biotherapeutics company, whose mission is to address the unmet needs of critically ill patients by developing and commercializing novel treatments. The new Ikaria was formed on March 27th, 2007, when Seattle-based research and discovery company Ikaria, Inc. combined with INO Therapeutics, a Clinton, NJ-based company with expertise in developing and commercializing drugs and novel treatments for the critically ill. Details of the transaction are given in the Financial History section. The original Ikaria is a biotechnology company focused on the discovery and research of breakthrough products for critical care. At the forefront of a new research domain in metabolic depression, the company is rapidly pursuing the development of products that may change critical care medicine. The company's technology is based on early research on metabolic control performed by MacArthur Award winner Mark Roth, Ph.D., an investigator at the Fred Hutchinson Cancer Research Center. Ikaria was founded in 2005 by Arch Venture Partners, the Fred Hutchinson Cancer Research Center (FHCRC), and Mark Roth, Ph.D., to commercialize research conducted in Dr. Roth's laboratory at the FHCRC. The original INO Therapeutics is a specialty pharmaceutical company with strengths in the development, marketing and sales of critical care drugs and devices that fulfill unmet medical needs. The company's core product is INOmax® (nitric oxide) for inhalation, which is the only pharmaceutical gas approved in the United States. Furthermore, the company is developing carbon monoxide as a novel therapeutic agent, bolstering its role as the leading company in the research, development, and commercialization of pharmaceutical gases and biologic gasomediators. |